These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 36414794

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dental defects in the primary dentition associated with hypophosphatasia from biallelic ALPL mutations.
    Kramer K, Chavez MB, Tran AT, Farah F, Tan MH, Kolli TN, Dos Santos EJL, Wimer HF, Millán JL, Suva LJ, Gaddy D, Foster BL.
    Bone; 2021 Feb; 143():115732. PubMed ID: 33160095
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia.
    Hofmann C, Seefried L, Jakob F.
    Drugs Today (Barc); 2016 May; 52(5):271-85. PubMed ID: 27376160
    [Abstract] [Full Text] [Related]

  • 11. Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl-/- mice by administration of soluble (non-targeted) chimeric alkaline phosphatase.
    Gasque KC, Foster BL, Kuss P, Yadav MC, Liu J, Kiffer-Moreira T, van Elsas A, Hatch N, Somerman MJ, Millán JL.
    Bone; 2015 Mar; 72():137-47. PubMed ID: 25433339
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Enzyme replacement therapy for hypophosphatasia-The current paradigm.
    Schindeler A, Ludwig K, Munns CF.
    Clin Endocrinol (Oxf); 2024 Dec; 101(6):593-601. PubMed ID: 39004952
    [Abstract] [Full Text] [Related]

  • 17. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
    Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K.
    Mol Genet Metab; 2017 Sep; 122(1-2):4-17. PubMed ID: 28888853
    [Abstract] [Full Text] [Related]

  • 18. Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasia.
    Stürznickel J, Schmidt FN, von Vopelius E, Delsmann MM, Schmidt C, Jandl NM, Oheim R, Barvencik F.
    Bone; 2021 Feb; 143():115794. PubMed ID: 33301963
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Japanese single-center experience of the efficacy and safety of asfotase alfa in pediatric-onset hypophosphatasia.
    Sugiyama Y, Watanabe T, Tajika M, Matsuhashi T, Shimura M, Fushimi T, Ichimoto K, Matsunaga A, Ebihara T, Tsuruoka T, Akiyama T, Murayama K.
    Orphanet J Rare Dis; 2022 Feb 23; 17(1):78. PubMed ID: 35197081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.